siddaruda m biradar

Abstract: Omeprazole is a substituted benzimidazole that has gained widespread use in the treatment of acidic and peptic ulcer diseases. Though the adverse events with the drug are rare and involve mainly skin inflammation, urticaria, pruritus, alopecia and dry skin have been reported in 0.5-1.5% of patients. There are very few reports linked to angioedema and urticaria pertaining to Omeprazole or class of PPI as an adverse reaction. Hereby a case of 26-year-old male with hypersensitivity reaction characterized by angioedema (Swelling of lips and fore head). The patient develops adverse drug reaction to Omeprazole may become a hypersensitivity to whole class of PPIs; hence it is to be safer to consider the change of class of drugs for his future correspondence. Simultaneously, all the prescribers should be aware of this possible phenomenon of angioedema while prescribing omeprazole for different clinical indications.

Epidermolysis bullosa (EB) is a rare and genetically determined skin fragility disorders. It has many genetic and symptomatic variations, but all share the prominent symptom of extremely fragile skin that blisters and tears from minor friction to trauma. It is always painful, often pervasive and debilitating. Its affects 1 out of every 50,000 live births and those born with it are often called ‘Butterfly Children’ that is delicate and fragile as butterfly wings. As there is no standard protocol for the treatment of EB and clinic features remains multiple and varied, hence treatment for the disease remains a major challenge. Therefore the current therapy focuses on prevention of progression of disease, nutritional support, bandage dressing and psychological support to the parents/guardians. Hence the platform provides this is a scope for discovery and development new drugs/treatment strategic plans for the treatment of Eidermolysis bullosa in order to recede the innocent babies’ agony.